Sign In
Buy JAGX
$2.17
-0.0800 (-3.56%)
At Close: Jul 14, 2026
Company remains sharply focused on its ongoing global development program for crofelemer for rare IF diseases Near-term milestones for IF program buttressed by continuing groundbreaking results of stu
Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend
09:00am, Thursday, 25'th Jun 2026
Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure diseases Reminder: Two crofelemer presentations in pediatric intestinal failure pat
Jaguar's recently completed pivotal effectiveness study of crofelemer for the treatment of CID in dogs demonstrates positive, statistically significant results SAN FRANCISCO, CA / ACCESS Newswire / Ju
Reminder: Lisa Conte, Jaguar's founder & CEO, to present on June 24, 2026 at the Life Sciences Virtual Investor Forum to provide updates on company's crofelemer development program for rare intestinal
Whole leaf coca extract under evaluation is Magdalena's drug candidate for post GLP-1 weight loss managementToronto, Ontario--(Newsfile Corp. - June
Whole leaf coca extract under evaluation is Magdalena's drug candidate for post-GLP-1 weight loss management SAN FRANCISCO, CA / ACCESS Newswire / June 18, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("J
Click here to register for event To access the replay of the June 10, 2026 presentation by Lisa Conte, Jaguar's founder, president & CEO, at the Emerging Growth Conference, click here Reminder: Two cr
Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders
04:15pm, Monday, 08'th Jun 2026
Lisa Conte, Jaguar's founder, president & CEO, presenting virtually on June 10, 2026 at the Emerging Growth Conference; click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 8, 2026 / Jagu
Crofelemer delayed-release tablets are Jaguar's FDA-approved prescription drug under botanical guidance ("botanical drug") derived from the Croton lechleri tree. Crofelemer, in a novel liquid formulat
Jaguar Health Compliant with Nasdaq Bid Price Rule
09:00am, Wednesday, 27'th May 2026
JAGX's securities continue to be listed and traded on Nasdaq SAN FRANCISCO, CA / ACCESS Newswire / May 27, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on
Jaguar Health, Inc. (JAGX) Q1 2026 Earnings Call Prepared Remarks Transcript
10:37am, Tuesday, 26'th May 2026
Jaguar Health, Inc. (JAGX) Q1 2026 Earnings Call Prepared Remarks Transcript
Jaguar Health Reports First Quarter 2026 Financials
04:40pm, Wednesday, 20'th May 2026
Net revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs.
Click here to register for Jaguar's May 26 webcast; Click here to register for May 28 virtual presentation at Lytham Partners Conference Company plans to file its Earnings Report on May 20, 2026 on Fo
First MVID patient enters the active treatment only extension phase after completion of randomized double-blind crossover period to evaluate longer-term safety and efficacy with liquid oral crofelemer
SAN FRANCISCO, CA / ACCESS Newswire / May 8, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided an update on the status of the Company's listing on The Nasdaq Stock Ma
